GLP-1 Market
LLY $1208.74 ▲ +3.6% NVO $38.12 ▲ +0.2% PFE $29.21 ▲ +3.0% VKTX $25.47 ▼ -4.4% KLRA $10.74 ▼ -0.3% GPCR $21.88 ▼ -1.9% RHHBY $55.67 ▲ +3.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pegfilgrastim

Company
Memorial Sloan Kettering Cancer Center
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
32 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

32 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 15, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pegfilgrastim and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01624805

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

    Not yet reported M.D. Anderson Cancer Center 140 participants Est. completion 2029-06-30 1 site Stand-alone
    Other conditions: Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
    View official trial listing →
  • Recruiting NCT NCT02582697

    Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

    Not yet reported University of Sydney 500 participants Est. completion 2029-12-31 56 sites Stand-alone
    Other conditions: Germ Cell Tumor
    View official trial listing →
  • Recruiting NCT NCT03136146

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

    Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2027-08-01 1 site Stand-alone
    Other conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03214562

    Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 116 participants Est. completion 2027-09-30 1 site Stand-alone
    Other conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT04628767

    Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) 131 participants Est. completion 2027-09-30 257 sites Stand-alone
    Other conditions: Renal Pelvis and Ureter Urothelial Carcinoma
    View official trial listing →
  • Recruiting NCT NCT04684368

    A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

    Not yet reported Children's Oncology Group 160 participants Est. completion 2029-12-21 170 sites Stand-alone
    Other conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
    View official trial listing →
  • Recruiting NCT NCT04685616

    Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

    Not yet reported University College, London 1042 participants Est. completion 2032-09 72 sites
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04872543

    A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

    Not yet reported Memorial Sloan Kettering Cancer Center 25 participants Est. completion 2027-04 7 sites Stand-alone
    Other conditions: Malignant Peripheral Nerve Sheath Tumors (MPNST)
    View official trial listing →
  • Recruiting NCT NCT05535166

    Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

    Not yet reported St. Jude Children's Research Hospital 130 participants Est. completion 2035-07 10 sites Stand-alone
    Other conditions: Medulloblastoma
    View official trial listing →
  • Recruiting NCT NCT05634369

    A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

    Not yet reported, Not yet reported Nationwide Children's Hospital 50 participants Est. completion 2027-12-01 22 sites Stand-alone
    Other conditions: Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
    View official trial listing →
  • Recruiting NCT NCT05645718

    Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

    Not yet reported M.D. Anderson Cancer Center 27 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Recruiting NCT NCT05753618

    Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

    Not yet reported Ottawa Hospital Research Institute 242 participants Est. completion 2026-10 3 sites Stand-alone
    Other conditions: Early-stage Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06023641

    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

    Not yet reported St. Jude Children's Research Hospital 135 participants Est. completion 2037-10 3 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Recruiting NCT NCT06048484

    Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

    Not yet reported Gulam Manji 60 participants Est. completion 2027-04 5 sites Stand-alone
    Other conditions: Pancreatic Ductal Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT06220032

    Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

    Not yet reported Stichting Hemato-Oncologie voor Volwassenen Nederland 324 participants Est. completion 2028-12-15 25 sites Stand-alone
    Other conditions: DLBCL - Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06269536

    Stress-reducing Intervention in Urothelial Carcinoma

    Not yet reported Comenius University 50 participants Est. completion 2029-02-15 1 site
    Other conditions: Bladder Cancer
    View official trial listing →
  • Recruiting NCT NCT06414889

    Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2027-06-30 1 site
    Other conditions: RUNX1 Familial Platelet Disorder
    View official trial listing →
  • Recruiting NCT NCT06520176

    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

    Not yet reported The Affiliated People's Hospital of Ningbo University 99 participants Est. completion 2026-12 16 sites Stand-alone
    Other conditions: Multiple Myeloma, Hematopoietic Stem Cell Mobilization
    View official trial listing →
  • Recruiting NCT NCT06528691

    Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

    Not yet reported St. Jude Children's Research Hospital 52 participants Est. completion 2032-11 6 sites Stand-alone
    Other conditions: High Grade Glioma, CNS Tumor
    View official trial listing →
  • Recruiting NCT NCT06594939

    Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

    Not yet reported Medical College of Wisconsin 31 participants Est. completion 2029-12 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma (DLBCL)
    View official trial listing →
  • Recruiting NCT NCT06616987

    Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

    Not yet reported Yeon Hee Park 40 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Recruiting NCT NCT06690775

    CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

    Not yet reported TORL Biotherapeutics, LLC 230 participants Est. completion 2027-12 66 sites Stand-alone
    Other conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
    View official trial listing →
  • Recruiting NCT NCT06709495

    Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

    Not yet reported, Not yet reported David S Shulman, MD 63 participants Est. completion 2029-09-01 3 sites Stand-alone
    Obstructive sleep apnea Other conditions: Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma
    View official trial listing →
  • Recruiting NCT NCT07021989

    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

    Not yet reported Michael Spinner, MD 38 participants Est. completion 2034-03-31 6 sites Stand-alone
    Other conditions: Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07064018

    Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

    Not yet reported, Not yet reported University of California, Irvine 67 participants Est. completion 2031-12-31 1 site Stand-alone
    Other conditions: Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
    View official trial listing →
  • Recruiting NCT NCT07125183

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

    Not yet reported University of Colorado, Denver 20 participants Est. completion 2029-12 1 site Stand-alone
    Other conditions: Sarcoma
    View official trial listing →
  • Recruiting NCT NCT07188090

    Mozobil for Autologous Hematopoietic Stem Cell Transplantation

    Not yet reported Thomas Jefferson University 100 participants Est. completion 2028-06 1 site
    Other conditions: Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07224100

    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

    Not yet reported University of Washington 33 participants Est. completion 2028-07-31 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07278856

    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

    Not yet reported City of Hope Medical Center 20 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type, Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
    View official trial listing →
  • Recruiting NCT NCT07419295

    A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

    Not yet reported Merck Sharp & Dohme LLC 590 participants Est. completion 2030-04-23 105 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Recruiting NCT NCT07525869

    An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

    Not yet reported Yonsei University 40 participants Est. completion 2026-10-27 2 sites Stand-alone
    Other conditions: Triple-Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07738991

    A Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of NKF-PEG, and US-Neulasta in Healthy Adult Male Volunteers

    Not yet reported Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. 202 participants Est. completion 2027-04-12 1 site
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT00002618

    Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma

    Not yet reported Children's Oncology Group 242 participants Est. completion 2006-09 10 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00003955

    Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

    Not yet reported Children's Oncology Group 77 participants Est. completion 2009-10 237 sites
    Other conditions: Sarcoma
    View official trial listing →
  • Completed NCT NCT00004192

    Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

    Not yet reported University of Nebraska 60 participants Est. completion 2001-03-16 3 sites Stand-alone
    Other conditions: Lymphoma, Neutropenia
    View official trial listing →
  • Completed NCT NCT00004853

    Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy

    Not yet reported National Cancer Institute (NCI) 34 participants Est. completion 2009-05-20 1 site
    Obstructive sleep apnea Other conditions: Ewing's Sarcoma, MPNST, Synovial Sarcoma, High-risk Sarcoma
    View official trial listing →
  • Completed NCT NCT00006011

    Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

    Not yet reported Gynecologic Oncology Group 659 participants 1 site Stand-alone
    Other conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer
    View official trial listing →
  • Completed NCT NCT00007904

    Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

    Not yet reported Case Comprehensive Cancer Center 16 participants Est. completion 2012-09 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00014534

    Combination Chemotherapy in Treating Patients With Bladder Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 42 participants Est. completion 2009-04 285 sites
    Other conditions: Bladder Cancer
    View official trial listing →
  • Status unknown NCT NCT00030758

    Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer

    Not yet reported Anglo Celtic Cooperative Oncology Group 816 participants 32 sites
    Other conditions: Breast Cancer, Neutropenia
    View official trial listing →
  • Completed NCT NCT00031629

    Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

    Not yet reported Gynecologic Oncology Group 51 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Recurrent Uterine Corpus Sarcoma
    View official trial listing →
  • Completed NCT NCT00035594

    Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

    Not yet reported Amgen 928 participants Est. completion 2004-06 Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT00035620

    Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

    Not yet reported Amgen 44 participants Est. completion 2007-04 Stand-alone
    Other conditions: Sarcoma, Neutropenia
    View official trial listing →
  • Completed NCT NCT00038545

    A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

    Not yet reported M.D. Anderson Cancer Center 25 participants Est. completion 2004-04-27 1 site
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00038558

    Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

    Not yet reported M.D. Anderson Cancer Center 25 participants Est. completion 2005-03 1 site
    Other conditions: Hodgkin Disease
    View official trial listing →
  • Completed NCT NCT00049595

    Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 552 participants 140 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00050674

    Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

    Not yet reported Schwartzberg, Lee, M.D. 40 participants Est. completion 2007-02 2 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00061984

    Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 455 participants Est. completion 2012-07 41 sites
    Other conditions: Sarcoma
    View official trial listing →
  • Terminated NCT NCT00063934

    Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) 31 participants Est. completion 2008-02 1 site Stand-alone
    Other conditions: Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT00063999

    Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

    Not yet reported GOG Foundation 1381 participants Est. completion 2021-01-05 650 sites
    Other conditions: Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT00066092

    Pegfilgrastim PBPC Mobilization Study

    Not yet reported Amgen 41 participants Est. completion 2004-10 Stand-alone
    Other conditions: Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology, Oncology
    View official trial listing →
  • Completed NCT NCT00066443

    Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

    Not yet reported, Not yet reported NCIC Clinical Trials Group 93 participants Est. completion 2014-01-16 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00067639

    Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2007-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00068393

    Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

    Not yet reported Eastern Cooperative Oncology Group 39 participants Est. completion 2011-05 92 sites
    Other conditions: Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
    View official trial listing →
  • Completed NCT NCT00069953

    Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

    Not yet reported Radiation Therapy Oncology Group 43 participants Est. completion 2016-12 97 sites Stand-alone
    Other conditions: Esophageal Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00070564

    S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

    Not yet reported SWOG Cancer Research Network 3294 participants Est. completion 2027-01 542 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00073983

    Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

    Not yet reported Sarcoma Alliance for Research through Collaboration 54 participants Est. completion 2010-12
    Other conditions: Sarcoma
    View official trial listing →
  • Terminated NCT NCT00074165

    Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

    Not yet reported OHSU Knight Cancer Institute 17 participants Est. completion 2010-12 2 sites Stand-alone
    Other conditions: Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00074178

    Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

    Not yet reported OHSU Knight Cancer Institute 22 participants Est. completion 2006-07 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00075634

    Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

    Not yet reported National Cancer Institute (NCI) 21 participants 1 site Stand-alone
    Other conditions: Recurrent Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00077103

    Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

    Not yet reported, Not yet reported Case Comprehensive Cancer Center 4 participants Est. completion 2007-12 3 sites
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT00077311

    Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 160 participants Est. completion 2009-04 64 sites Stand-alone
    Other conditions: Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
    View official trial listing →
  • Terminated NCT NCT00080626

    Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19 participants Est. completion 2006-05-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00086944

    Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 25 participants 1 site Stand-alone
    Other conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT00092222

    Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

    Not yet reported National Cancer Institute (NCI) 75 participants Est. completion 2026-10-01 1 site
    Other conditions: Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
    View official trial listing →
  • Completed NCT NCT00094809

    Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

    Not yet reported Amgen 252 participants Est. completion 2008-01-23
    Other conditions: Colon Cancer, Colorectal Cancer, Rectal Cancer
    View official trial listing →
  • Completed NCT NCT00094822

    Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Amgen 90 participants Est. completion 2006-02
    Other conditions: Lung Cancer, Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00101010

    Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 80 participants Est. completion 2014-09 7 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00101127

    Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

    Not yet reported Gynecologic Oncology Group 60 sites
    Other conditions: Sarcoma
    View official trial listing →
  • Completed NCT NCT00107510

    Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 58 participants 120 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00113386

    Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer

    Not yet reported Radiation Therapy Oncology Group 19 participants 76 sites
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00113789

    Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer

    Not yet reported Amgen 21 participants Est. completion 2005-04
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00113932

    UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma

    Not yet reported University of Arkansas 140 participants Est. completion 2010-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00114764

    Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

    Not yet reported Amgen 84 participants Est. completion 2004-08 Stand-alone
    Other conditions: Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00115193

    Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

    Not yet reported Amgen 77 participants Est. completion 2005-08
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00115206

    Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

    Not yet reported Amgen Est. completion 2004-07
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00115414

    Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

    Not yet reported Amgen
    Other conditions: Breast Cancer, Fever, Neutropenia
    View official trial listing →
  • Completed NCT NCT00117442

    A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

    Not yet reported Amgen 61 participants Est. completion 2004-12 Stand-alone
    Other conditions: Breast Cancer, Lung Cancer, Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00117455

    A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma

    Not yet reported Amgen
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00117897

    Treatment for Subjects With Non-Hodgkin's Lymphoma

    Not yet reported Amgen Est. completion 2004-02
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00117910

    Treatment for Elderly Patients With High Risk Breast Cancer

    Not yet reported Amgen Est. completion 2004-05
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00118209

    Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 524 participants Est. completion 2021-11-15 47 sites
    Other conditions: Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00119262

    Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

    Not yet reported National Cancer Institute (NCI) 226 participants Est. completion 2009-09 1 site Stand-alone
    Other conditions: Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
    View official trial listing →
  • Completed NCT NCT00124111

    A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

    Not yet reported Amgen
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00125723

    FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy

    Not yet reported Amgen 2252 participants Est. completion 2005-12
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT00146562

    Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

    Not yet reported Harold J. Burstein, MD, PhD 135 participants Est. completion 2007-05 6 sites
    Other conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
    View official trial listing →
  • Completed NCT NCT00151242

    Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported, Not yet reported University of Ulm 920 participants Est. completion 2013-08 34 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00166439

    Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

    Not yet reported Academic and Community Cancer Research United 50 participants Est. completion 2015-09 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00169143

    Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

    Not yet reported Lymphoma Study Association 60 participants Est. completion 2007-01 6 sites
    Other conditions: Untreated CD20-positive Large B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00187031

    A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor

    Not yet reported St. Jude Children's Research Hospital 37 participants Est. completion 2007-10 7 sites
    Other conditions: Wilms Tumor
    View official trial listing →
  • Completed NCT NCT00189137

    Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

    Not yet reported University of Michigan Rogel Cancer Center 84 participants Est. completion 2015-10 1 site
    Other conditions: Sarcoma, Soft Tissue
    View official trial listing →
  • Completed NCT NCT00193206

    Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

    Not yet reported SCRI Development Innovations, LLC 123 participants Est. completion 2009-05 13 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00193479

    Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

    Not yet reported SCRI Development Innovations, LLC 51 participants Est. completion 2010-02 2 sites Stand-alone
    Other conditions: Non-Hodgkins Lymphoma
    View official trial listing →
  • Completed NCT NCT00211185

    A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

    Not yet reported Eisai Inc. 49 participants Est. completion 2009-12-23 49 sites Stand-alone
    Other conditions: Lymphoma, T-Cell, Peripheral
    View official trial listing →
  • Completed NCT NCT00217503

    Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

    Not yet reported National Cancer Institute (NCI) 15 participants Est. completion 2007-06 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00217529

    Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 3 sites
    Other conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
    View official trial listing →
  • Completed NCT NCT00217568

    Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

    Not yet reported Fred Hutchinson Cancer Center 3 sites
    Other conditions: Ovarian Cancer, Peritoneal Cavity Cancer
    View official trial listing →
  • Completed NCT NCT00232479

    Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

    Not yet reported University of Miami 48 participants Est. completion 2008-06 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00240097

    Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)

    Not yet reported University of Alabama at Birmingham 30 participants Est. completion 2010-06 1 site
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00253500

    Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

    Not yet reported Case Comprehensive Cancer Center 15 participants Est. completion 2010-12 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00254410

    FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2017-09-14 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00256360

    Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer

    Not yet reported Universitaire Ziekenhuizen KU Leuven 117 participants Est. completion 2006-05 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00261313

    ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

    Not yet reported Amgen 80 participants Est. completion 2007-12
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00277160

    A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

    Not yet reported Amgen 852 participants Est. completion 2005-01 Stand-alone
    Other conditions: Neutropenia, Breast Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00278161

    Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 94 participants Est. completion 2011-07 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00280787

    Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

    Not yet reported UNC Lineberger Comprehensive Cancer Center 24 participants Est. completion 2010-10 1 site
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00283621

    Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

    Not yet reported M.D. Anderson Cancer Center 51 participants Est. completion 2006-04-12 1 site Stand-alone
    Other conditions: Sarcoma
    View official trial listing →
  • Completed NCT NCT00286819

    Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer

    Not yet reported Central European Cooperative Oncology Group 50 participants Est. completion 2006-09 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00290667

    Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

    Not yet reported German High-Grade Non-Hodgkin's Lymphoma Study Group 586 participants Est. completion 2015-11 338 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00291850

    Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC

    Not yet reported Central European Cooperative Oncology Group 50 participants 5 sites
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT00301925

    Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

    Not yet reported Institute of Cancer Research, United Kingdom 4400 participants Est. completion 2024-09 152 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00304070

    Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

    Not yet reported Children's Oncology Group 78 participants Est. completion 2023-06-30 91 sites Stand-alone
    Other conditions: Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
    View official trial listing →
  • Completed NCT NCT00306111

    Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

    Not yet reported University Hospital Tuebingen 14 participants Est. completion 2011-12 1 site Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00310089

    AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

    Not yet reported National Cancer Institute (NCI) 33 participants Est. completion 2007-07 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00333008

    A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

    Not yet reported The Alvin and Lois Lapidus Cancer Institute 27 participants 2 sites
    Other conditions: Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Active, not recruiting NCT NCT00334815

    Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

    Not yet reported National Cancer Institute (NCI) 29 participants Est. completion 2027-02-22 61 sites Stand-alone
    Other conditions: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT00346125

    PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

    Not yet reported Masonic Cancer Center, University of Minnesota 70 participants Est. completion 2022-07 2 sites
    Other conditions: Sarcoma
    View official trial listing →
  • Terminated NCT NCT00346229

    Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

    Not yet reported Duke University 29 participants Est. completion 2011-04 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00352118

    Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

    Not yet reported Masonic Cancer Center, University of Minnesota 4 participants Est. completion 2008-04 1 site Stand-alone
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT00352300

    Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

    Not yet reported Gynecologic Oncology Group 43 participants 11 sites Stand-alone
    Obstructive sleep apnea Other conditions: Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00364468

    Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

    Not yet reported Kyowa Kirin Co., Ltd. 107 participants Est. completion 2008-03 6 sites
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT00389818

    Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

    Not yet reported AIDS Malignancy Consortium 43 participants Est. completion 2011-09 14 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00392834

    Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

    Not yet reported AIDS Malignancy Consortium 34 participants Est. completion 2013-07 13 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00394251

    Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

    Not yet reported Celgene 197 participants Est. completion 2008-02-01 27 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00404066

    Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

    Not yet reported George Albert Fisher 21 participants Est. completion 2011-03 2 sites Stand-alone
    Other conditions: Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00410696

    Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

    Not yet reported Armando Santoro, MD 80 participants Est. completion 2008-11 1 site Stand-alone
    Other conditions: Hematological Neoplasms, Tumors
    View official trial listing →
  • Completed NCT NCT00431080

    Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

    Not yet reported Hellenic Oncology Research Group 478 participants Est. completion 2007-10 10 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00433420

    Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

    Not yet reported IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 2000 participants Est. completion 2027-12
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00433537

    Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 77 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00436709

    Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 75 participants 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00453232

    Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 20 participants Est. completion 2009-01 7 sites
    Other conditions: Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor
    View official trial listing →
  • Completed NCT NCT00466258

    LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

    Not yet reported PETHEMA Foundation 50 participants Est. completion 2009-11 15 sites
    Other conditions: HIV Infections, Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00470366

    Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

    Not yet reported Memorial Sloan Kettering Cancer Center 60 participants Est. completion 2016-06 2 sites Stand-alone
    Other conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
    View official trial listing →
  • Completed NCT NCT00472849

    Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 92 participants Est. completion 2012-02 1 site Stand-alone
    Other conditions: Richter's Transformation, Leukemia
    View official trial listing →
  • Completed NCT NCT00478361

    Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2015-06 2 sites Stand-alone
    Other conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
    View official trial listing →
  • Completed NCT NCT00482391

    Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 95 participants Est. completion 2011-07 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00493870

    TAC Versus TC for Adjuvant Breast Cancer

    Not yet reported US Oncology Research 1961 participants Est. completion 2020-03-30 95 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00496795

    Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer

    Not yet reported University of Bergen 100 participants Est. completion 2026-05 1 site
    Other conditions: Stage III Breast Cancer AJCC V7
    View official trial listing →
  • Status unknown NCT NCT00499018

    Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

    Not yet reported Fondazione Italiana Linfomi - ETS 399 participants Est. completion 2013-09 75 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, IPI≥2
    View official trial listing →
  • Completed NCT NCT00503750

    Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)

    Not yet reported Emory University 27 participants Est. completion 2011-07 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00503984

    A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

    Not yet reported, Not yet reported University of Miami 22 participants Est. completion 2015-06 1 site Stand-alone
    Other conditions: Prostate Cancer, Pain
    View official trial listing →
  • Terminated NCT NCT00515138

    A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

    Not yet reported University of California, San Francisco 7 participants Est. completion 2011-11 1 site
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT00515411

    Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

    Not yet reported Memorial Sloan Kettering Cancer Center 111 participants Est. completion 2018-10-26 15 sites
    Other conditions: Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
    View official trial listing →
  • Status unknown NCT NCT00516425

    Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer

    Not yet reported Charing Cross Hospital 1000 participants 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00526734

    High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

    Not yet reported Erasme University Hospital 100 participants 4 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00536081

    Various G-CSF Regimens to Prevent Infection During Chemotherapy

    Not yet reported Academisch Ziekenhuis Maastricht 172 participants Est. completion 2016-12-01 21 sites Stand-alone
    Other conditions: Breast Cancer, Chemotherapy, Febrile Neutropenia
    View official trial listing →
  • Completed NCT NCT00546377

    Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 50 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00551122

    Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

    Not yet reported, Not yet reported University of Southampton 23 participants 3 sites Stand-alone
    Other conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
    View official trial listing →
  • Completed NCT NCT00554463

    G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

    Not yet reported Radiation Therapy Oncology Group 5 participants Est. completion 2011-08-03 14 sites Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00558220

    R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas

    Not yet reported Czech Lymphoma Study Group 106 participants Est. completion 2006-10 8 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma., Primary Mediastinal B-Cell Lymphoma, Follicular Lymphoma Grade III
    View official trial listing →
  • Completed NCT NCT00569673

    Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

    Not yet reported Gynecologic Oncology Group 71 participants 37 sites
    Other conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    View official trial listing →
  • Terminated NCT NCT00574080

    UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

    Not yet reported University of Arkansas 20 participants Est. completion 2011-03 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00575952

    Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

    Not yet reported Gynecologic Oncology Group 27 participants Est. completion 2016-07-16 9 sites Stand-alone
    Other conditions: Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
    View official trial listing →
  • Completed NCT NCT00588094

    Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

    Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2010-03 1 site
    Other conditions: Lymphoma, B-cell Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00602420

    Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

    Not yet reported Gary Morrow 510 participants Est. completion 2012-03 16 sites Stand-alone
    Other conditions: Musculoskeletal Complications, Pain, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00612989

    Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM

    Not yet reported Duke University 42 participants Est. completion 2008-07 1 site
    Obstructive sleep apnea Other conditions: Glioblastoma
    View official trial listing →
  • Completed NCT NCT00615602

    Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

    Not yet reported Hellenic Oncology Research Group 489 participants Est. completion 2012-05 10 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00615901

    Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 38 participants Est. completion 2010-06 5 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00617370

    Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

    Not yet reported Memorial Sloan Kettering Cancer Center 38 participants Est. completion 2008-06 1 site Stand-alone
    Other conditions: Breast Cancer, Adenocarcinoma of the Breast
    View official trial listing →
  • Terminated NCT NCT00632827

    Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

    Not yet reported University of California, San Francisco 21 participants Est. completion 2016-06-23 1 site Stand-alone
    Other conditions: Peripheral T-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00645333

    Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported University of Michigan Rogel Cancer Center 30 participants Est. completion 2012-10 3 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00662519

    Neulasta in Type 1 Diabetes

    Not yet reported University of Florida 21 participants Est. completion 2014-03 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00667615

    Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 30 participants Est. completion 2017-02 5 sites
    Other conditions: Hodgkin's Disease, Lymphoma
    View official trial listing →
  • Completed NCT NCT00669877

    Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

    Not yet reported M.D. Anderson Cancer Center 56 participants Est. completion 2015-10 1 site Stand-alone
    Other conditions: Burkitt's Lymphoma, Burkitt'S-like Lymphoma
    View official trial listing →
  • Completed NCT NCT00670358

    Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

    Not yet reported, Not yet reported Mayo Clinic 138 participants Est. completion 2024-10-04 3 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00671658

    Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 220 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Leukemia, Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00678327

    Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

    Not yet reported University College, London 1202 participants Est. completion 2024-05-01 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00679029

    Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

    Not yet reported University of Nebraska 15 participants Est. completion 2010-11-18 1 site Stand-alone
    Other conditions: HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00681044

    HD Melphalan and SCT in Patients With IGDD or LCDD

    Not yet reported Boston Medical Center 5 participants Est. completion 2016-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00682383

    Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

    Not yet reported Mt. Sinai Medical Center, Miami 26 participants Est. completion 2010-01 1 site
    Other conditions: Unresectable Locally Advanced NSCLC
    View official trial listing →
  • Terminated NCT NCT00689884

    Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

    Not yet reported Dartmouth-Hitchcock Medical Center 7 participants Est. completion 2009-01 1 site Stand-alone
    Other conditions: Hematologic Malignancies
    View official trial listing →
  • Terminated NCT NCT00695370

    Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

    Not yet reported University Hospital, Clermont-Ferrand 30 participants Est. completion 2008-01
    Other conditions: Solid Malignancies
    View official trial listing →
  • Terminated NCT NCT00700011

    Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

    Not yet reported Texas Oncology Cancer Center 10 participants Est. completion 2010-03 1 site
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00705250

    Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 36 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Hodgkin's Disease, Lymphoma
    View official trial listing →
  • Completed NCT NCT00726700

    Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

    Not yet reported Universität des Saarlandes 109 participants Est. completion 2012-02 Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00751894

    Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)

    Not yet reported University Hospital, Clermont-Ferrand 30 participants 1 site
    Other conditions: Solid Malignancies
    View official trial listing →
  • Status unknown NCT NCT00777673

    Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

    Not yet reported University of Tennessee Cancer Institute 60 participants Est. completion 2013-10 3 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00787969

    Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 74 participants Est. completion 2017-06-15 144 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00794261

    Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma

    Not yet reported Centre Leon Berard 150 participants Est. completion 2010-06 11 sites Stand-alone
    Other conditions: Lymphoma, Myeloma
    View official trial listing →
  • Completed NCT NCT00807599

    Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

    Not yet reported Memorial Sloan Kettering Cancer Center 67 participants Est. completion 2018-07 7 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00808639

    Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

    Not yet reported Dana-Farber Cancer Institute 39 participants Est. completion 2016-09 4 sites Stand-alone
    Other conditions: Bladder Cancer, Muscle-invasive Bladder Cancer
    View official trial listing →
  • Completed NCT NCT00812669

    CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

    Not yet reported Cancer Trials Ireland 52 participants Est. completion 2019-11-21 7 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00816595

    Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported Mayo Clinic 68 participants Est. completion 2016-11-29 2 sites Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00837265

    Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

    Not yet reported, Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 334 participants Est. completion 2009-06-26
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Completed NCT NCT00856492

    S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

    Not yet reported SWOG Cancer Research Network 215 participants Est. completion 2015-12 366 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT00881387

    Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

    Not yet reported University of Miami Est. completion 2012-10 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00886509

    Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients

    Not yet reported Insel Gruppe AG, University Hospital Bern 50 participants Est. completion 2015-02 2 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00887536

    A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

    Not yet reported NSABP Foundation Inc 1613 participants Est. completion 2018-02 533 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00887809

    Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

    Not yet reported Memorial Sloan Kettering Cancer Center 47 participants Est. completion 2014-11 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Sarcoma, Malignant Fibrous, Histiocytoma
    View official trial listing →
  • Completed NCT NCT00893399

    Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

    Not yet reported University of Ulm 600 participants Est. completion 2021-09-01 60 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00911170

    PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

    Not yet reported Amgen 847 participants Est. completion 2015-01-02 154 sites
    Other conditions: Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
    View official trial listing →
  • Completed NCT NCT00911183

    Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial

    Not yet reported Institut Bergonié 67 participants Est. completion 2015-01-01 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00935961

    RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 18 participants Est. completion 2013-08 5 sites Stand-alone
    Other conditions: HEAD & NECK Cancer
    View official trial listing →
  • Completed NCT NCT00938678

    Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers

    Not yet reported Hospira, now a wholly owned subsidiary of Pfizer 71 participants Est. completion 2009-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00944047

    Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

    Not yet reported University of Kansas Medical Center 32 participants Est. completion 2017-08 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00968253

    RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 24 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Leukemia, Acute Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00969826

    Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor

    Not yet reported Seoul National University Hospital 38 participants Est. completion 2009-09 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00971763

    Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

    Not yet reported University College, London 62 participants Est. completion 2011-07 4 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00974792

    Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

    Not yet reported Cancer Research UK 150 participants 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT01012297

    Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

    Not yet reported National Cancer Institute (NCI) 107 participants Est. completion 2015-09 201 sites Stand-alone
    Obstructive sleep apnea Other conditions: Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma
    View official trial listing →
  • Completed NCT NCT01037543

    Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

    Not yet reported Hanmi Pharmaceutical Company Limited 84 participants Est. completion 2011-04 1 site
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT01046825

    Mature B-Cell Lymphoma And Leukemia Study III

    Not yet reported, Not yet reported St. Jude Children's Research Hospital 128 participants Est. completion 2027-08 4 sites
    Other conditions: Mature B-Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT01057069

    Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer

    Not yet reported, Not yet reported The Netherlands Cancer Institute 310 participants Est. completion 2029-12 14 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01059643

    A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

    Not yet reported Eli Lilly and Company 103 participants Est. completion 2012-12 18 sites Stand-alone
    Other conditions: Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck
    View official trial listing →
  • Withdrawn NCT NCT01067274

    ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)

    Not yet reported Acute Leukemia French Association 26 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01076504

    A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

    Not yet reported SCRI Development Innovations, LLC 81 participants Est. completion 2015-03 20 sites Stand-alone
    Other conditions: Extensive-Stage Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT01106157

    Reversing Type 1 Diabetes After it is Established

    Not yet reported, Not yet reported University of Florida 25 participants Est. completion 2019-07-16 3 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Terminated NCT NCT01111942

    A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer

    Not yet reported Southern Illinois University 4 participants Est. completion 2014-01 1 site
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Terminated NCT NCT01120171

    Myocet Plus Endoxan for Older Patients With Breast Cancer

    Not yet reported Hellenic Oncology Research Group 64 participants Est. completion 2015-05 11 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01125787

    Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

    Not yet reported Nevada Cancer Institute 1 participants Est. completion 2011-04 2 sites
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Completed NCT NCT01126190

    Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

    Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 381 participants Est. completion 2012-02-29 59 sites
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Withdrawn NCT NCT01131247

    PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

    Not yet reported Nevada Cancer Institute 37 participants 1 site
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Completed NCT NCT01169636

    Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 62 participants Est. completion 2017-05-17 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01172912

    High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 47 participants 1 site
    Other conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
    View official trial listing →
  • Completed NCT NCT01214629

    A Study for Participants With Advanced Cancer

    Not yet reported Eli Lilly and Company 54 participants Est. completion 2012-05 2 sites Stand-alone
    Other conditions: Advanced Cancer, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT01214642

    A Dose-Escalation Study for Patients With Advanced Cancer

    Not yet reported Eli Lilly and Company 63 participants Est. completion 2012-06 2 sites Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT01256398

    Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Not yet reported National Cancer Institute (NCI) 66 participants Est. completion 2021-11-15 101 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    View official trial listing →
  • Terminated NCT NCT01258634

    A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

    Not yet reported University of Chicago 2 participants Est. completion 2011-11 1 site
    Obstructive sleep apnea Other conditions: Lung Metastases
    View official trial listing →
  • Completed NCT NCT01266447

    Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

    Not yet reported National Cancer Institute (NCI) 27 participants Est. completion 2016-01 78 sites Stand-alone
    Other conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
    View official trial listing →
  • Completed NCT NCT01297452

    BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

    Not yet reported Memorial Sloan Kettering Cancer Center 45 participants Est. completion 2017-03-29 1 site Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Status unknown NCT NCT01311336

    Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain

    Not yet reported University of Vermont 55 participants Est. completion 2013-06 7 sites
    Other conditions: Pegfilgrastim-induced Back and Leg Pain
    View official trial listing →
  • Terminated NCT NCT01313884

    Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

    Not yet reported Stanford University 3 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Bone Cancer, Ewing's Sarcoma
    View official trial listing →
  • Completed NCT NCT01319981

    Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 31 participants Est. completion 2020-11-11 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT01328938

    GCPGC in Chemotherapy-induced Neutropenia

    Not yet reported, Not yet reported Green Cross Corporation 177 participants Est. completion 2013-05 15 sites
    Other conditions: Chemotherapy Induced Neutropenia
    View official trial listing →
  • Completed NCT NCT01355705

    Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Michaela Liedtke 14 participants Est. completion 2017-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01385228

    Pazopanib, Docetaxel, Prednisone Prostate

    Not yet reported Daniel George, MD 36 participants Est. completion 2016-02 2 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01416246

    Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant

    Not yet reported Memorial Sloan Kettering Cancer Center 26 participants Est. completion 2016-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01416389

    A Study of LY2523355 in Participants With Breast Cancer

    Not yet reported Eli Lilly and Company 39 participants Est. completion 2013-09 12 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01437488

    Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 14 participants Est. completion 2017-03-30 3 sites
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT01446458

    Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

    Not yet reported Emory University 13 participants Est. completion 2015-03 2 sites
    Other conditions: Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
    View official trial listing →
  • Completed NCT NCT01491841

    IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

    Not yet reported Anne Beaven, MD 33 participants Est. completion 2017-02-17 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01497002

    Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a

    Not yet reported University of Leipzig 1222 participants Est. completion 2018-07-18 1 site Stand-alone
    Other conditions: Acute Myeloid Leukaemia
    View official trial listing →
  • Terminated NCT NCT01498588

    Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

    Not yet reported Emory University 7 participants Est. completion 2015-06 4 sites Stand-alone
    Other conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
    View official trial listing →
  • Completed NCT NCT01501487

    MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

    Not yet reported Agendia 226 participants Est. completion 2017-06 9 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01516736

    Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

    Not yet reported Sandoz 308 participants Est. completion 2013-12 53 sites
    Other conditions: Chemotherapy-induced Neutropenia, Breast Cancer
    View official trial listing →
  • Completed NCT NCT01519700

    Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

    Not yet reported Sandoz 218 participants Est. completion 2013-06 26 sites
    Other conditions: Chemotherapy Associated Neutropenia, Breast Cancer
    View official trial listing →
  • Completed NCT NCT01527422

    Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL

    Not yet reported, Not yet reported Fernando Cabanillas 60 participants Est. completion 2011-03 1 site
    Other conditions: Lymphoma, Non Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT01533207

    Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

    Not yet reported Gynecologic Oncology Group 38 participants Est. completion 2019-02-09 623 sites Stand-alone
    Obstructive sleep apnea Other conditions: Stage I Uterine Sarcoma AJCC v7
    View official trial listing →
  • Terminated NCT NCT01541072

    Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation

    Not yet reported Centre Leon Berard 34 participants Est. completion 2014-09 2 sites Stand-alone
    Other conditions: Non Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01557959

    Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Not yet reported Wake Forest University Health Sciences 45 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT01585649

    PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

    Not yet reported Merckle GmbH 21 participants Est. completion 2015-04 18 sites
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT01594918

    Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

    Not yet reported Rahul Aggarwal 25 participants Est. completion 2017-06-23 3 sites Stand-alone
    Other conditions: Metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT01637493

    Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients

    Not yet reported Hangzhou Jiuyuan Gene Engineering Co. Ltd., 24 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Terminated NCT NCT01639131

    Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 6 participants Est. completion 2019-03-11 3 sites Stand-alone
    Other conditions: Metastatic Colorectal Adenocarcinoma
    View official trial listing →
  • Withdrawn NCT NCT01639521

    Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

    Not yet reported University of Southern California Est. completion 2013-05 Stand-alone
    Other conditions: Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer, Urethral Cancer Associated With Invasive Bladder Cancer
    View official trial listing →
  • Completed NCT NCT01648322

    Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

    Not yet reported EVIVE Biotechnology 232 participants Est. completion 2014-12 1 site
    Other conditions: Breast Cancer, Neutropenia
    View official trial listing →
  • Completed NCT NCT01654965

    Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

    Not yet reported National Cancer Institute (NCI) 17 participants Est. completion 2018-03-29 7 sites Stand-alone
    Other conditions: Adult Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT01657331

    Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

    Not yet reported, Not yet reported Columbia University 65 participants Est. completion 2018-06 3 sites Stand-alone
    Other conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01671319

    Dose Dense TC + Pegfilgrastim Support for Breast Cancer

    Not yet reported University of Wisconsin, Madison 42 participants Est. completion 2013-04 1 site Stand-alone
    Other conditions: Female Breast Cancer
    View official trial listing →
  • Completed NCT NCT01682044

    Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

    Not yet reported Roswell Park Cancer Institute 20 participants Est. completion 2016-12-22 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT01692691

    Dacarbazine and Carmustine in Metastatic Melanoma

    Not yet reported Western Regional Medical Center 1 participants Est. completion 2014-10 1 site
    Other conditions: Melanoma Metastatic
    View official trial listing →
  • Completed NCT NCT01701076

    Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Cantonal Hospital of St. Gallen 50 participants Est. completion 2016-02 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01712009

    NOLAN: Naproxen or Loratadine and Neulasta

    Not yet reported Amgen 600 participants Est. completion 2015-03-18 83 sites Stand-alone
    Other conditions: Bone Pain in Stage I - III Breast Cancer
    View official trial listing →
  • Completed NCT NCT01724866

    Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

    Not yet reported Spectrum Pharmaceuticals, Inc 148 participants Est. completion 2014-08-12 27 sites Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT01735175

    Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®

    Not yet reported Sandoz 316 participants Est. completion 2014-02 41 sites Stand-alone
    Other conditions: Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
    View official trial listing →
  • Withdrawn NCT NCT01750866

    Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

    Not yet reported Case Comprehensive Cancer Center Est. completion 2013-10
    Other conditions: Castrate-resistant Metastatic Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01752907

    Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim

    Not yet reported Amgen 304 participants Est. completion 2014-12-15 51 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01782339

    A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis

    Not yet reported Barts & The London NHS Trust 45 participants Est. completion 2021-05-05 1 site Stand-alone
    Other conditions: Germ Cell Tumour
    View official trial listing →
  • Active, not recruiting NCT NCT01783535

    Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

    Not yet reported St. Jude Children's Research Hospital 174 participants Est. completion 2027-02-21 1 site
    Other conditions: Retinoblastoma
    View official trial listing →
  • Completed NCT NCT01805557

    Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

    Not yet reported, Not yet reported Fondazione Italiana Linfomi - ETS 108 participants Est. completion 2020-11-20 24 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
    View official trial listing →
  • Completed NCT NCT01806337

    CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

    Not yet reported University of Göttingen 41 participants Est. completion 2011-02
    Other conditions: Peripheral T-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01827163

    Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2019-01 4 sites Stand-alone
    Other conditions: HER2-Positive Early Stage Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT01840566

    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 17 participants Est. completion 2027-04 7 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01840579

    Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

    Not yet reported Merck Sharp & Dohme LLC 57 participants Est. completion 2020-02-28 Stand-alone
    Other conditions: Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT01847001

    Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

    Not yet reported Columbia University 10 participants Est. completion 2019-10-16 1 site Stand-alone
    Other conditions: Locally Advanced Malignant Neoplasm, Breast Cancer
    View official trial listing →
  • Completed NCT NCT01850888

    MIBG for Refractory Neuroblastoma and Pheochromocytoma

    Not yet reported Masonic Cancer Center, University of Minnesota 15 participants Est. completion 2025-10-20 1 site
    Other conditions: Relapsed Neuroblastoma, Metastatic Pheochromocytoma
    View official trial listing →
  • Terminated NCT NCT01859637

    Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

    Not yet reported Sandoz 6 participants Est. completion 2015-09 2 sites
    Other conditions: Severe Chronic Neutropenia
    View official trial listing →
  • Active, not recruiting NCT NCT01871766

    Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    Not yet reported St. Jude Children's Research Hospital 115 participants Est. completion 2030-06 4 sites
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT01879085

    Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

    Not yet reported, Not yet reported Melissa Burgess, MD 37 participants Est. completion 2021-04-15 1 site Stand-alone
    Other conditions: Sarcoma
    View official trial listing →
  • Completed NCT NCT01896856

    Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

    Not yet reported, Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 118 participants Est. completion 2019-08-26 4 sites
    Other conditions: Previously Treated Metastatic Colorectal Cancer
    View official trial listing →
  • Status unknown NCT NCT01918241

    Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

    Not yet reported Hangzhou Jiuyuan Gene Engineering Co. Ltd., 200 participants 1 site Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Active, not recruiting NCT NCT01933932

    Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

    Not yet reported AstraZeneca 510 participants Est. completion 2026-12-31 197 sites
    Other conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
    View official trial listing →
  • Completed NCT NCT01985724

    Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

    Not yet reported Hellenic Oncology Research Group 650 participants Est. completion 2013-12 10 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02044276

    A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

    Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 101 participants Est. completion 2018-04-24 60 sites
    Other conditions: Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
    View official trial listing →
  • Completed NCT NCT02073097

    Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

    Not yet reported, Not yet reported Case Comprehensive Cancer Center 48 participants Est. completion 2023-06-29 3 sites Stand-alone
    Other conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT02087176

    A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

    Not yet reported AstraZeneca 48 participants Est. completion 2015-05 12 sites Stand-alone
    Other conditions: Previously Treated Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02098109

    Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

    Not yet reported Washington University School of Medicine 100 participants Est. completion 2016-09-18 1 site
    Other conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT02142049

    Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    Not yet reported, Not yet reported Pharmacyclics LLC. 35 participants Est. completion 2017-08 10 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
    View official trial listing →
  • Terminated NCT NCT02157116

    Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

    Not yet reported Duke University 13 participants Est. completion 2010-01 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02178475

    Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

    Amgen 943 participants Est. completion 2016-10-28 74 sites
    Other conditions: Chemotherapy-induced Febrile Neutropenia
    View official trial listing →
  • Completed NCT NCT02181218

    Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

    Not yet reported Washington University School of Medicine 24 participants Est. completion 2020-06-26 2 sites Stand-alone
    Other conditions: Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Status unknown NCT NCT02205320

    A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers

    Not yet reported Dr. Reddy's Laboratories Limited 192 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Pharmacokinetics
    View official trial listing →
  • Completed NCT NCT02215200

    ATG-GCSF in New Onset Type 1 Diabetes

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 89 participants Est. completion 2018-08 13 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Status unknown NCT NCT02238873

    Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma

    Not yet reported Rabin Medical Center 300 participants 1 site Stand-alone
    Other conditions: Lymphoma, Neutropenia
    View official trial listing →
  • Completed NCT NCT02306915

    PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

    Not yet reported Merckle GmbH 48 participants Est. completion 2015-05 1 site
    Other conditions: Pharmacokinetics, Pharmacodynamics
    View official trial listing →
  • Completed NCT NCT02369458

    Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

    Not yet reported Washington University School of Medicine 48 participants Est. completion 2024-11-01 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
    View official trial listing →
  • Terminated NCT NCT02374424

    Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients

    Not yet reported Fondazione Italiana Linfomi - ETS 29 participants Est. completion 2020-06-23 10 sites Stand-alone
    Other conditions: Diffuse, Large B-Cell, Lymphoma
    View official trial listing →
  • Terminated NCT NCT02379585

    Fasting on Newly Diagnosed Breast Cancer

    Not yet reported, Not yet reported Western Regional Medical Center 8 participants Est. completion 2015-08 1 site
    Other conditions: HER2-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT02385851

    Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

    Not yet reported Coherus Oncology, Inc. 116 participants Est. completion 2015-07 1 site Stand-alone
    Other conditions: Bioequivalence
    View official trial listing →
  • Terminated NCT NCT02392039

    Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

    Not yet reported M.D. Anderson Cancer Center 1 participants Est. completion 2018-04-04 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT02392793

    Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

    Not yet reported St. Jude Children's Research Hospital 43 participants Est. completion 2019-08-30 1 site
    Other conditions: Childhood Solid Tumors
    View official trial listing →
  • Completed NCT NCT02412670

    Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

    Not yet reported ECOG-ACRIN Cancer Research Group 36 participants Est. completion 2022-05-10 134 sites Stand-alone
    Other conditions: High Grade Upper Tract Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT02418104

    Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

    Not yet reported Coherus Oncology, Inc. 303 participants Est. completion 2015-12 4 sites
    Other conditions: Immunity, Humoral
    View official trial listing →
  • Status unknown NCT NCT02431403

    ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Pusan National University Hospital 94 participants 5 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT02467868

    Efficacy and Safety Study With MYL-1401H and Neulasta

    Not yet reported Mylan Inc. 193 participants Est. completion 2016-02 36 sites
    Other conditions: Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia
    View official trial listing →
  • Terminated NCT NCT02469116

    Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

    Not yet reported Washington University School of Medicine 18 participants Est. completion 2010-03 1 site
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Status unknown NCT NCT02474550

    Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

    Ajou University School of Medicine 1000 participants Est. completion 2020-12 24 sites
    Other conditions: Diffuse Large B Cell Lymphoma, Neutropenia, Febrile
    View official trial listing →
  • Completed NCT NCT02479646

    Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta

    Not yet reported Mylan Inc. 218 participants Est. completion 2015-06 1 site
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Status unknown NCT NCT02488382

    Lonquek for Autologous Stem Cell Mobilization

    Not yet reported, Not yet reported Sheba Medical Center 24 participants Est. completion 2020-07 1 site
    Other conditions: Lymphoma, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02511132

    A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

    Not yet reported Gradalis, Inc. 22 participants Est. completion 2020-12-23 6 sites
    Other conditions: Ewing's Sarcoma
    View official trial listing →
  • Completed NCT NCT02527317

    Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer

    Beaumont Hospital 40 participants Est. completion 2018-02 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02531308

    Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

    Not yet reported Rush University Medical Center 5 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT02533362

    ANF-Rho in the Treatment of Chronic Neutropenia

    Not yet reported, Not yet reported Prolong Pharmaceuticals Est. completion 2016-10 Stand-alone
    Other conditions: Neutropenia, Severe Chronic
    View official trial listing →
  • Completed NCT NCT02543255

    Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)

    Not yet reported University Health Network, Toronto 76 participants Est. completion 2021-07-20 5 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT02578732

    FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

    Not yet reported Brown University 28 participants Est. completion 2022-03-16 1 site
    Other conditions: Locally Advanced Pancreatic Cancer, Pancreatic Cancer
    View official trial listing →
  • Withdrawn NCT NCT02586831

    Diabetes Islet Preservation Immune Treatment

    Not yet reported, Not yet reported Camillo Ricordi and Jay Skyler Est. completion 2024-06-01
    Other conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02589301

    Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations

    Not yet reported Eurofarma Laboratorios S.A. 100 participants Est. completion 2016-11 1 site Stand-alone
    Other conditions: Neutropenia, Healthy
    View official trial listing →
  • Withdrawn NCT NCT02592395

    Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma

    Not yet reported The University of Texas Health Science Center, Houston Est. completion 2017-10
    Other conditions: Pancreatic Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT02629289

    A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

    Not yet reported Pfizer 153 participants Est. completion 2016-06 1 site
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT02629562

    Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects

    Not yet reported Cinfa Biotech 172 participants 1 site
    Other conditions: Clinical Pharmacology
    View official trial listing →
  • Completed NCT NCT02643420

    SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

    Not yet reported Spectrum Pharmaceuticals, Inc 406 participants Est. completion 2018-10-31 81 sites Stand-alone
    Other conditions: Neutropenia, Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02649673

    LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

    Not yet reported SCRI Development Innovations, LLC 34 participants Est. completion 2021-07-30 3 sites Stand-alone
    Other conditions: Small Cell Lung Cancer, Ovarian Cancer
    View official trial listing →
  • Terminated NCT NCT02650635

    TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

    Not yet reported Mayo Clinic 4 participants Est. completion 2017-06-01 1 site Stand-alone
    Other conditions: Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT02650973

    Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

    Not yet reported Coherus Oncology, Inc. 122 participants Est. completion 2016-06 4 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT02685111

    Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

    Not yet reported Asan Medical Center 22 participants Est. completion 2017-12 1 site
    Other conditions: Breast Cancer, Neutropenia, Febrile Neutropenia
    View official trial listing →
  • Completed NCT NCT02698891

    Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

    Not yet reported Dana-Farber Cancer Institute 127 participants Est. completion 2021-11 4 sites Stand-alone
    Other conditions: Early Stage Breast Cancer
    View official trial listing →
  • Completed NCT NCT02728531

    Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

    Not yet reported Washington University School of Medicine 18 participants Est. completion 2023-08-16 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT02768714

    Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy

    Not yet reported Eurofarma Laboratorios S.A. Est. completion 2019-10 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02776059

    Pegfilgrastim in Patients With Alcoholic Hepatitis

    Not yet reported Timothy Morgan, MD 34 participants Est. completion 2021-03-31 5 sites Stand-alone
    Other conditions: Alcoholic Hepatitis
    View official trial listing →
  • Completed NCT NCT02782845

    An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

    Not yet reported Hoffmann-La Roche 53 participants Est. completion 2007-10 19 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02790580

    Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients

    Not yet reported National University Hospital, Singapore 98 participants Est. completion 2020-11 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02805153

    PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

    Not yet reported CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 215 participants Est. completion 2016-02 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02805166

    PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

    Not yet reported CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 420 participants Est. completion 2016-02 Stand-alone
    Other conditions: Malignant Solid Tumors
    View official trial listing →
  • Completed NCT NCT02805205

    PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia

    Not yet reported CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 484 participants Est. completion 2016-02 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02805218

    PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

    Not yet reported CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 410 participants Est. completion 2016-02 Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02810743

    Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

    Not yet reported The Netherlands Cancer Institute 174 participants Est. completion 2033-12-01 11 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02834403

    L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

    Not yet reported, Not yet reported The Methodist Hospital Research Institute 37 participants Est. completion 2021-01 1 site Stand-alone
    Other conditions: Metastatic Triple Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT02840539

    Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

    Not yet reported Seoul National University Hospital 19 participants Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02909036

    Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

    Not yet reported Memorial Sloan Kettering Cancer Center 46 participants Est. completion 2027-09 1 site Stand-alone
    Other conditions: Multiple Myeloma, Amyloidosis
    View official trial listing →
  • Completed NCT NCT02912377

    Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects

    Not yet reported Cinfa Biotech 96 participants Est. completion 2017-05 1 site
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02921191

    Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated

    Biologics & Biosimilars Collective Intelligence Consortium 57725 participants Est. completion 2019-02
    Other conditions: Breast Cancer, Lung Cancer
    View official trial listing →
  • Completed NCT NCT02938442

    Vaccination of Triple Negative Breast Cancer Patients

    Not yet reported, Not yet reported University of Arkansas 16 participants Est. completion 2023-01-09 2 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer, Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT02943733

    Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

    Not yet reported University of Wisconsin, Madison 18 participants Est. completion 2022-01-31 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
    View official trial listing →
  • Completed NCT NCT02953340

    SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

    Not yet reported Spectrum Pharmaceuticals, Inc 237 participants Est. completion 2019-05-06 74 sites Stand-alone
    Other conditions: Neutropenia, Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02983097

    Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

    Not yet reported, Not yet reported Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 34 participants Est. completion 2015-04-28 12 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL), Aggressive Marginal Zone Lymphoma (MZL)
    View official trial listing →
  • Completed NCT NCT03036488

    Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

    Not yet reported Merck Sharp & Dohme LLC 1174 participants Est. completion 2025-10-14 193 sites
    Other conditions: Triple Negative Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT03102606

    Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

    Not yet reported BeyondSpring Pharmaceuticals Inc. 105 participants Est. completion 2021-02-08 18 sites Stand-alone
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Completed NCT NCT03107988

    NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

    Not yet reported New Approaches to Neuroblastoma Therapy Consortium 65 participants Est. completion 2025-01-31 13 sites Stand-alone
    Other conditions: Neuroblastoma
    View official trial listing →
  • Completed NCT NCT03146988

    Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

    Not yet reported Gedeon Richter Plc. 150 participants Est. completion 2017-10-04 1 site Stand-alone
    Other conditions: Bioequivalence
    View official trial listing →
  • Active, not recruiting NCT NCT03147612

    Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2027-02-28 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT03188198

    Risk Adapted Therapy in Diffuse Large B Cell Lymphoma

    Not yet reported Mansoura University 60 participants Est. completion 2019-06-01 1 site
    Other conditions: Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03197935

    A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 333 participants Est. completion 2022-09-28 68 sites Stand-alone
    Other conditions: Triple-negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT03202927

    Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

    Not yet reported Adello Biologics, LLC 102 participants Est. completion 2018-04-12 2 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03206229

    Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects

    Not yet reported Adello Biologics, LLC 120 participants Est. completion 2018-01-18 1 site
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Active, not recruiting NCT NCT03220022

    Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

    Not yet reported National Cancer Institute (NCI) 46 participants Est. completion 2027-07-16 19 sites Stand-alone
    Other conditions: AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03251248

    Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

    Not yet reported Fresenius Kabi SwissBioSim GmbH 294 participants Est. completion 2018-10-17 2 sites
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03251339

    Safety and Immunogenicity of MSB11455 in Healthy Participants

    Not yet reported Fresenius Kabi SwissBioSim GmbH 336 participants Est. completion 2018-09-22 2 sites
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03252431

    Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

    Not yet reported EVIVE Biotechnology 393 participants Est. completion 2020-03-05 1 site
    Other conditions: Breast Cancer, Neutropenia
    View official trial listing →
  • Completed NCT NCT03273842

    A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

    Not yet reported Pfizer 422 participants Est. completion 2018-07-25 4 sites
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Status unknown NCT NCT03294577

    Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

    Not yet reported BeyondSpring Pharmaceuticals Inc. 221 participants Est. completion 2025-09-25 20 sites Stand-alone
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Completed NCT NCT03301350

    Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

    Not yet reported University of Wisconsin, Madison 29 participants Est. completion 2022-02-07 6 sites Stand-alone
    Other conditions: Breast Cancer, Triple Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03329378

    Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

    Not yet reported Icahn School of Medicine at Mount Sinai 7 participants Est. completion 2021-03-07 3 sites
    Other conditions: Locally Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT03376503

    Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

    Not yet reported Nanogen Pharmaceutical Biotechnology Joint Stock Company 24 participants Est. completion 2017-11-06 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03381417

    Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

    Not yet reported Nanogen Pharmaceutical Biotechnology Joint Stock Company 128 participants Est. completion 2017-11-06 1 site Stand-alone
    Other conditions: Breast Cancer Female
    View official trial listing →
  • Status unknown NCT NCT03404752

    Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

    Not yet reported Gema Biotech S.A. 120 participants Est. completion 2018-12 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03407430

    Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain

    Not yet reported UNC Lineberger Comprehensive Cancer Center 11 participants Est. completion 2017-07-20 1 site Stand-alone
    Other conditions: Breast Cancer, Lymphoma, Pain
    View official trial listing →
  • Completed NCT NCT03433560

    An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)

    Kyowa Kirin Korea Co., Ltd. 1300 participants Est. completion 2021-06-30 3 sites
    Other conditions: Breast Cancer Female, Breast Neoplasm Female
    View official trial listing →
  • Status unknown NCT NCT03435289

    A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

    Not yet reported Atlantic Health System 24 participants Est. completion 2019-01 2 sites
    Other conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT03471611

    Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

    Not yet reported Mayo Clinic 21 participants Est. completion 2020-10-02 1 site
    Other conditions: Atherosclerosis, Coronary
    View official trial listing →
  • Completed NCT NCT03511378

    Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

    Not yet reported Lupin Ltd. 138 participants Est. completion 2019-01-09 17 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03518112

    Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 6 participants Est. completion 2021-05-27 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT03559387

    Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

    Not yet reported Prolong Pharmaceuticals 9 participants Est. completion 2018-05-22 8 sites
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Active, not recruiting NCT NCT03571633

    Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

    Not yet reported Centre Leon Berard 90 participants Est. completion 2027-09 9 sites Stand-alone
    Other conditions: HER2-positive Breast Cancer, Operable Breast Cancer
    View official trial listing →
  • Completed NCT NCT03575520

    Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients

    Not yet reported Yonsei University 63 participants Est. completion 2017-03-15 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03609216

    Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

    Not yet reported Alliance for Clinical Trials in Oncology 237 participants Est. completion 2029-02-01 424 sites Stand-alone
    Other conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT03619993

    Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

    Not yet reported iOMEDICO AG 404 participants Est. completion 2019-09-10 48 sites Stand-alone
    Other conditions: Non Hodgkin Lymphoma, Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03639948

    Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

    Not yet reported University of Kansas Medical Center 120 participants Est. completion 2024-11 9 sites Stand-alone
    Other conditions: Triple-negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03646123

    Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

    Not yet reported Seagen Inc. 255 participants Est. completion 2024-08-23 76 sites
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • No Longer Available NCT NCT03649438

    131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

    University of Texas Southwestern Medical Center 1 site
    Other conditions: Relapsed Neuroblastoma, Metastatic Pheochromocytoma
    View official trial listing →
  • Status unknown NCT NCT03798665

    A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors

    Affiliated Hospital of North Sichuan Medical College 800 participants Est. completion 2019-07-06 1 site
    Other conditions: Neutropenia
    View official trial listing →
  • Status unknown NCT NCT03846414

    Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

    CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 1500 participants Est. completion 2020-10-01
    Other conditions: Chemotherapy-induced Neutropenia, Myelosuppression
    View official trial listing →
  • Completed NCT NCT03885284

    Study of Proton Therapy in Adjuvant Pancreatic Cancer

    Not yet reported Georgetown University 9 participants Est. completion 2023-11-08 1 site Stand-alone
    Other conditions: Resected Pancreatic Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03907488

    Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 994 participants Est. completion 2027-03-28 728 sites Stand-alone
    Other conditions: Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03943901

    Split-Dose R-CHOP for Older Adults With DLBCL

    Not yet reported University of Wisconsin, Madison 27 participants Est. completion 2027-02 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, DLBCL, Cancer
    View official trial listing →
  • Completed NCT NCT03993639

    KRN125 for Mobilization of Hematopoietic Stem Cells

    Not yet reported Kyowa Kirin Co., Ltd. 35 participants Est. completion 2020-08-28 1 site Stand-alone
    Other conditions: Peripheral Blood Stem Cell Transplantation
    View official trial listing →
  • Completed NCT NCT04014062

    Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

    Not yet reported Intas Pharmaceuticals, Ltd. 144 participants Est. completion 2018-05-01 1 site Stand-alone
    Other conditions: Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04015232

    Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

    Not yet reported Intas Pharmaceuticals, Ltd. 200 participants Est. completion 2018-06-05 1 site Stand-alone
    Other conditions: Immunogenicity, Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04023669

    Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

    Not yet reported St. Jude Children's Research Hospital 21 participants Est. completion 2025-01-13 1 site Stand-alone
    Other conditions: Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
    View official trial listing →
  • Terminated NCT NCT04156828

    Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

    Not yet reported University of Washington 12 participants Est. completion 2023-06-08 1 site Stand-alone
    Other conditions: Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT04173585

    TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

    Not yet reported University Hospital Heidelberg 50 participants Est. completion 2023-03-24 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04174742

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

    Wake Forest University Health Sciences 115 participants Est. completion 2041-01 2 sites
    Other conditions: Breast, Breast Cancer
    View official trial listing →
  • Completed NCT NCT04227990

    Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

    Not yet reported BeyondSpring Pharmaceuticals Inc. 115 participants Est. completion 2019-01-03 11 sites Stand-alone
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Completed NCT NCT04294641

    Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

    Not yet reported National Cancer Institute (NCI) 10 participants Est. completion 2024-10-01 2 sites Stand-alone
    Other conditions: Chronic GVHD
    View official trial listing →
  • Active, not recruiting NCT NCT04323956

    Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

    Not yet reported Mayo Clinic 50 participants Est. completion 2028-05-16 3 sites Stand-alone
    Other conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT04345900

    Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

    Not yet reported BeyondSpring Pharmaceuticals Inc. 55 participants Est. completion 2018-04-20 19 sites
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Completed NCT NCT04383743

    Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

    Not yet reported University of Washington 17 participants Est. completion 2025-03-04 1 site Stand-alone
    Other conditions: Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
    View official trial listing →
  • Completed NCT NCT04460079

    Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN

    Cinnagen 654 participants Est. completion 2019-09-07
    Other conditions: Chemotherapy-induced Neutropenia
    View official trial listing →
  • Completed NCT NCT04477616

    Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 160 participants Est. completion 2022-11-06 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04506554

    A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

    Not yet reported Fox Chase Cancer Center 81 participants Est. completion 2028-11 4 sites
    Other conditions: Muscle-Invasive Bladder Carcinoma
    View official trial listing →
  • Completed NCT NCT04584112

    A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 83 participants Est. completion 2023-03-08 24 sites Stand-alone
    Other conditions: Triple-Negative Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04651036

    A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

    Not yet reported Qilu Pharmaceutical Co., Ltd. 300 participants Est. completion 2022-11-30 2 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04661852

    Cabozantinib With Topotecan-Cyclophosphamide

    Not yet reported Dana-Farber Cancer Institute 12 participants Est. completion 2022-10-24 2 sites Stand-alone
    Obstructive sleep apnea Other conditions: Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
    View official trial listing →
  • Status unknown NCT NCT04662892

    An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

    Coherus Oncology, Inc. 200 participants Est. completion 2022-12-15 3 sites
    Other conditions: Febrile Neutropenia, Non-myeloid Malignancy
    View official trial listing →
  • Completed NCT NCT04687098

    Risk-adapted Therapy for Primary Acute Myeloid Leukemia

    Not yet reported Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias 1034 participants Est. completion 2022-11-10 15 sites
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Active, not recruiting NCT NCT04759586

    Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 244 participants Est. completion 2026-12-31 233 sites Stand-alone
    Other conditions: Primary Mediastinal Large B-Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04762901

    LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

    Not yet reported Wake Forest University Health Sciences Est. completion 2026-01 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04781959

    A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

    Not yet reported Ottawa Hospital Research Institute 233 participants Est. completion 2023-09-28 2 sites
    Other conditions: Early-stage Breast Cancer
    View official trial listing →
  • Completed NCT NCT04873765

    Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers

    Not yet reported Megalabs 72 participants Est. completion 2022-09-18 1 site Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT04971304

    Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars

    Catherine M. Lockhart 16506 participants Est. completion 2022-12-31
    Other conditions: Cancer, Breast, Cancer, Lung, Cancer of Colon, Cancer of Pancreas, Cancer, Ovarian, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT05007652

    A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

    Not yet reported Kyowa Kirin Co., Ltd. 64 participants Est. completion 2022-10-25 21 sites Stand-alone
    Other conditions: Multiple Myeloma and Malignant Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05011188

    FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

    Not yet reported, Not yet reported Rahul Aggarwal 44 participants Est. completion 2027-07-31 1 site Stand-alone
    Other conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT05032183

    Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2024-07-31 1 site Stand-alone
    Other conditions: Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT05043649

    Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

    Not yet reported Monopar Therapeutics 14 participants Est. completion 2024-05-13 2 sites Stand-alone
    Other conditions: Advanced Soft-tissue Sarcoma
    View official trial listing →
  • Active, not recruiting NCT NCT05130827

    Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

    Not yet reported Memorial Sloan Kettering Cancer Center 17 participants Est. completion 2026-11 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05194579

    Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe

    Not yet reported Pfizer 141 participants Est. completion 2022-08-10 4 sites
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Active, not recruiting NCT NCT05211336

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

    Not yet reported National Cancer Institute (NCI) 14 participants Est. completion 2029-06-01 1 site
    Other conditions: Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
    View official trial listing →
  • Completed NCT NCT05283616

    Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

    Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 122 participants Est. completion 2021-10-15 1 site Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT05296317

    Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration

    Not yet reported Centre Georges Francois Leclerc 97 participants Est. completion 2025-09-26 1 site Stand-alone
    Other conditions: Localized Breast Cancer
    View official trial listing →
  • Completed NCT NCT05338047

    Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

    Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 30 participants Est. completion 2023-02-25 1 site
    Other conditions: Myeloma Multiple, Lymphoma
    View official trial listing →
  • Completed NCT NCT05573386

    Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim

    Andrews Research & Education Foundation 15 participants Est. completion 2023-10-05 1 site
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT05834751

    the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

    Not yet reported Ou Bai, MD/PHD 144 participants Est. completion 2025-07-01 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05841186

    Correlation of Timing of Pegfilgrastim Administration and PIBP.

    Not yet reported Guangdong Provincial People's Hospital 156 participants Est. completion 2025-05-31 1 site
    Other conditions: Pegfilgrastim, Bone Pain, Chemotherapy, Breast Cancer, Patient-reported Outcomes, Quality of Life
    View official trial listing →
  • Terminated NCT NCT05870748

    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

    Not yet reported, Not yet reported Sutro Biopharma, Inc. 600 participants Est. completion 2025-08-26 63 sites Stand-alone
    Other conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT05910164

    Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim

    Institut Rafael 150 participants Est. completion 2024-10-09 1 site
    Other conditions: Patient Preference, Febrile Neutropenia, Drug-Induced, Patient Satisfaction
    View official trial listing →
  • Status unknown NCT NCT05949333

    Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

    Not yet reported Eunseong Medical Foundation Good GANG-AN HOSPITAL 100 participants Est. completion 2025-07 1 site
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT06094140

    NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

    Not yet reported Australasian Gastro-Intestinal Trials Group 20 participants Est. completion 2026-06 3 sites
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Status unknown NCT NCT06116734

    Lapelga vs Gastrofil

    Not yet reported London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 74 participants Est. completion 2025-11-01 Stand-alone
    Other conditions: Multiple Myeloma, Lymphoma, Engagement, Patient, Febrile Neutropenia
    View official trial listing →
  • Status unknown NCT NCT06168188

    The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

    Not yet reported Buddhist Tzu Chi General Hospital 20 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: Traumatic Optic Neuropathy
    View official trial listing →
  • Active, not recruiting NCT NCT06188676

    Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

    Not yet reported National Research Center for Hematology, Russia 60 participants Est. completion 2029-04-01 1 site Stand-alone
    Other conditions: Primary Mediastinal Lymphoma
    View official trial listing →
  • Completed NCT NCT06309732

    GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

    Not yet reported Queen Mary University of London 36 participants Est. completion 2014-01 1 site Stand-alone
    Other conditions: Testicular Neoplasms
    View official trial listing →
  • Completed NCT NCT06698861

    A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers

    Not yet reported PharmaEssentia 30 participants Est. completion 2025-02-06 1 site Stand-alone
    Other conditions: PK in Healthy Volunteers
    View official trial listing →
  • Active, not recruiting NCT NCT06711523

    Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

    Not yet reported Kexing Biopharm Co., Ltd. 250 participants Est. completion 2026-06-30 1 site
    Other conditions: Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female
    View official trial listing →
  • Suspended NCT NCT06738368

    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

    Not yet reported University of Washington 30 participants Est. completion 2028-07-30 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07059611

    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

    Not yet reported Abramson Cancer Center at Penn Medicine 34 participants Est. completion 2029-11-01 1 site Stand-alone
    Other conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07184021

    Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

    Not yet reported Assiut University 30 participants Est. completion 2027-09 1 site Stand-alone
    Other conditions: Urinary Bladder Cancer
    View official trial listing →
  • Completed NCT NCT07416955

    Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

    Not yet reported Kashiv BioSciences, LLC 180 participants Est. completion 2025-10-10 1 site
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Not yet recruiting NCT NCT07829783

    A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)

    Not yet reported Merck Sharp & Dohme LLC 400 participants Est. completion 2036-09-25 Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07848672

    Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization

    Not yet reported, Not yet reported The Affiliated People's Hospital of Ningbo University 70 participants Est. completion 2030-12-01 Stand-alone
    Other conditions: Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization, Chemotherapy-Induced Thrombocytopenia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Pegfilgrastim, STIMUFEND, UDENYCA, ZIEXTENZO, NYVEPRIA, Fulphila

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.